Theravectys Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $24.8M

  • Investors
  • 7

Theravectys General Information

Description

Developer of a therapeutic vaccination technology designed for critical needs to prevent and treat infectious diseases and cancer. The company's vaccination technology assists in modulating the immune response through gene transfer into dendritic cells and supports patients and healthcare providers by developing prophylactic and therapeutic immunotherapies across a pipeline, enabling physicians to treat patients through a transfection mechanism to elicit a potent and targeted immune response.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25-28 Rue du Docteur Roux
  • 75015 Paris
  • France
+33 06
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 25-28 Rue du Docteur Roux
  • 75015 Paris
  • France
+33 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Theravectys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 15-Feb-2021 $24.8M Completed Clinical Trials - Phase 1
9. Later Stage VC 18-Apr-2017 Completed Clinical Trials - Phase 1
8. Grant 26-Jan-2015 Completed Clinical Trials - Phase 1
7. Later Stage VC 16-Oct-2013 Completed Clinical Trials - Phase 1
6. Debt - General 29-May-2013 Completed Clinical Trials - Phase 1
5. Later Stage VC 04-Sep-2012 Completed Clinical Trials - Phase 1
4. Debt - General 01-Jan-2010 Completed Clinical Trials - Phase 1
3. Grant 01-Jan-2008 Completed Clinical Trials - Phase 1
2. Grant 01-Jan-2005 $433K Completed Startup
1. Early Stage VC 01-Jan-2005 Completed Startup
To view Theravectys’s complete valuation and funding history, request access »

Theravectys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
O Shares
To view Theravectys’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Theravectys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a therapeutic vaccination technology designed for critical needs to prevent and treat infectious diseases a
Drug Discovery
Paris, France
18 As of 2024

Maastricht, Netherlands
 

Madison, WI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Theravectys Competitors (59)

One of Theravectys’s 59 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Centrose Venture Capital-Backed Madison, WI
Virometix Venture Capital-Backed Schlieren, Switzerland
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Iovance Biotherapeutics Corporation San Carlos, CA
You’re viewing 5 of 59 competitors. Get the full list »

Theravectys Patents

Theravectys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4729068-A1 Lentiviral vector-based immunotherapy of prostate tumors Pending 16-Oct-2024
WO-2026082898-A1 Lentiviral vector-based immunotherapy of prostate tumors Pending 16-Oct-2024
WO-2026077941-A1 Lentiviral vectors targeting kras neoepitopes for cancer immunotherapy Pending 08-Oct-2024
AU-2023362558-A1 Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host Pending 21-Oct-2022
EP-4604993-A2 Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host Pending 21-Oct-2022 A61P31/12
To view Theravectys’s complete patent history, request access »

Theravectys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Theravectys Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Bpifrance Sovereign Wealth Fund Minority
FGP Capital Asset Manager Minority
Financière IDAT Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Theravectys FAQs

  • When was Theravectys founded?

    Theravectys was founded in 2005.

  • Where is Theravectys headquartered?

    Theravectys is headquartered in Paris, France.

  • What is the size of Theravectys?

    Theravectys has 18 total employees.

  • What industry is Theravectys in?

    Theravectys’s primary industry is Drug Discovery.

  • Is Theravectys a private or public company?

    Theravectys is a Private company.

  • What is the current valuation of Theravectys?

    The current valuation of Theravectys is .

  • What is Theravectys’s current revenue?

    The current revenue for Theravectys is .

  • How much funding has Theravectys raised over time?

    Theravectys has raised $64.7M.

  • Who are Theravectys’s investors?

    , , Bpifrance, FGP Capital, and Financière IDAT are 5 of 7 investors who have invested in Theravectys.

  • Who are Theravectys’s competitors?

    Cristal Therapeutics, Centrose, Virometix, Inovio Pharmaceuticals, and Iovance Biotherapeutics are some of the 59 competitors of Theravectys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process